What Referen Treats: Main Uses and Benefits

The therapeutic focus of Referen is generally used for acute symptomatic support, helping with comfort during periods of functional discomfort. This approach is a recognized method for providing symptomatic relief for acute conditions.

Referen is commonly used in clinical settings that involve heightened patient distress to address symptom clusters that may appear suddenly or intensify. It is considered relevant in conditions characterized by periods of heightened symptoms or those that present with disruptive symptom manifestations, providing supportive relief when symptoms interfere with routine activities. The medication is applied across domains where additional symptomatic support is needed, applied to address symptoms related to physical discomfort and symptoms that create noticeable physiological strain.

Quick Fact: Focus on Acute Symptom Management

Referen is commonly used to help manage symptoms related to physical discomfort and heightened physiological activity, particularly when symptoms create noticeable functional strain.

Regulatory References

1. NIH overview of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Eligibility Map: Who can and cannot use Referen

This section summarizes the official eligibility information for Referen, strictly based on governmental regulatory documents that define who can and cannot use a prescription medicine.

Official Eligibility Summary

Classification	Definition and Context
Populations for Whom Use is Contraindicated	These are clinical situations or prior medical conditions where the risk of using Referen clearly outweighs any potential therapeutic benefit. Referen is absolutely prohibited in these cases. All formal contraindications are explicitly listed in the drug's prescribing information.
Age-Related Restrictions	Use in specific age groups, such as pediatric patients or older adults, is determined by available data on safety and effectiveness. If specific data is lacking, use may be classified as "not established." Dosage adjustments or special monitoring may be required for older adults.
Condition-Specific Restrictions	Individuals with conditions affecting major organs, such as hepatic impairment (liver) or renal impairment (kidney), may require a different dosage or special consideration to prevent toxicity. These modifications are explicitly stated in the Dosage and Administration section.
Pregnancy and Lactation Status	The official labeling provides a detailed summary of known risks when Referen is administered during pregnancy or lactation, often based on available human and animal data. This information determines whether use is restricted or advised against based on the drug's approved eligibility profile.

Eligibility for Referen is established by the absence of a formal contraindication and by meeting any restrictions defined for specific populations. Regulatory documents ensure that all known eligibility constraints and safety considerations are clearly communicated to prevent harmful use.

Interactions with other medicines and products

The interaction profile for Iron Sucrose (Referen) is defined by its specific chemical structure and intravenous route of administration, leading to a restricted range of documented interactions in regulatory labeling.

Interaction Scope

Category	Official Regulatory Information
Medicinal product categories with documented interactions:	Oral Iron Preparations (e.g., Ferrous Sulphate, Ferrous Gluconate).
Mechanistic basis of interactions:	Pharmacodynamic interference resulting in reduced absorption of the oral iron compound.
Timing-based interaction rules:	Oral iron therapy must be started at least 5 days after the last injection of Iron Sucrose.
Interaction-related restrictions:	Co-administration of Iron Sucrose and oral iron preparations should not be administered concomitantly.

---

Interaction Classifications (High-Level)

Category	Official Regulatory Information
Interaction severity classification:	Clinically significant interaction requiring a mandatory administration interval.
Regulatory basis:	Summary of Product Characteristics (SmPC) and FDA Prescribing Information.

---

Resulting Interaction Structure

Official interaction statements specify that co-administration of Iron Sucrose with oral iron preparations is restricted because the intravenous iron reduces the absorption of the oral product. This necessitates a clear temporal separation. No clinically relevant pharmacokinetic interactions involving the Cytochrome P450 enzyme system, major drug transporters, food, alcohol, or herbal products are documented in the official labeling. The central regulatory constraint is the required 5-day separation period before initiating oral iron therapy following the last injection of Iron Sucrose, which defines the primary interaction-related procedural requirement.

Controlled Processing by the Reticuloendothelial System (RES)

The mechanism of Iron Sucrose begins with the complex being actively processed by macrophages within the reticuloendothelial system (RES). This cellular internalization and breakdown of the stable ferric hydroxide-sucrose core is essential for controlling the rate of Fe^3+ release. This kinetic control regulates the rate of Fe^3+ entry into the plasma, maintaining complex stability.

Targeted Transport and Substrate Replenishment

Once released from the macrophages, the iron is immediately captured by the transport protein transferrin. This transferrin-iron complex is delivered directly to the bone marrow, where it is taken up by erythroid precursor cells via the transferrin receptor (TfR). The iron then serves as the indispensable substrate for the synthesis of heme, a foundational step in creating new hemoglobin.

Cascade to Systemic Oxygen Capacity

The supply of iron substrate via this controlled pathway directly engages erythropoiesis, or red blood cell formation. By providing the critical building block, the mechanism culminates in an increased generation of functional hemoglobin. This physiological consequence contributes to an increase in the body's total capacity for oxygen transport at the tissue level.

How to Use Referen: Official Administration Guidelines

Referen (Iron Sucrose) is an iron replacement product that is administered solely via the intravenous (IV) route. Administration is restricted to either slow IV injection, IV infusion, or through the venous line of a dialyzer, and the product must not be given intramuscularly or subcutaneously.

The standard adult treatment course is typically a cumulative total of 1000 mg of elemental iron. This total course is delivered in divided doses over a set period, with the specific regimen depending on the patient's type of Chronic Kidney Disease (CKD).

Standard Dosing Regimens

CKD Status	Typical Single Dose	Frequency and Schedule
Hemodialysis-Dependent	100 mg elemental iron	Administered per consecutive hemodialysis session (up to three times weekly).
Non-Dialysis-Dependent	200 mg elemental iron	Administered on 5 separate occasions over a 14-day period.

Preparation and Procedural Constraints

The solution must be prepared by diluting only in 0.9% Sodium Chloride Injection, USP (normal saline), and the final infusion must meet specific concentration limits (e.g., between 1 mg and 2 mg iron per mL). The administration rate is strictly controlled to ensure safe delivery; for instance, a 200 mg dose must be infused over a minimum of 15 minutes. For pediatric patients (ages two years and older), the dose is calculated based on body weight, typically 0.5 mg/kg of elemental iron per administration, with a maximum dose of 100 mg. The administration of Iron Sucrose must occur in a setting where appropriate personnel and therapies are immediately available, requiring patient observation during and after the procedure.

Referen: Recent Clinical Evidence

Evidence for Use in Chronic Kidney Disease (CKD)

The most extensive research base, including Randomized Controlled Trials (RCTs), for Referen was studied for its role in addressing iron deficiency in people with Chronic Kidney Disease (CKD). Researchers primarily monitored objective hematological biomarkers, such as Hemoglobin (Hb) concentration, Serum Ferritin levels, and Transferrin Saturation (TSAT), along with changes in the rate of red blood cell transfusions. Findings describe patterns observed in the studies where treatment was associated with reported increases in Hemoglobin and Ferritin levels. While the initial correction of iron stores is often the focus of the research, long-term effects are not fully established, and data remains insufficient regarding patient-reported quality of life over extended periods.

---

Evidence for Use in Inflammatory Bowel Disease (IBD)

Referen was evaluated in research exploring its role in addressing iron deficiency anemia associated with Inflammatory Bowel Disease (IBD). This research often involved randomized open-label trials that also included oral iron supplements as a comparator. Studies examined patients with IBD who had iron deficiency, often even when underlying inflammation was present. Findings indicate that changes in hematological biomarkers were observed in the studied populations. Limited information for long-term outcomes is available regarding the sustained maintenance of iron stores and the optimal dosing frequency over several years for patients with IBD.

---

What is Still Uncertain About Referen's Evidence

Research has explored the use of Referen to address iron deficiency in individuals with Heart Failure (HF) who have a reduced pumping function. Findings describe patterns observed where iron repletion was associated with reported changes in functional capacity and symptom scores. However, a large portion of the contemporary evidence in the HF population involves newer intravenous iron formulations, meaning data specifically for Referen may be limited and heterogeneous. Consequently, data are still emerging. The optimal frequency and total lifetime dose of Referen for individuals requiring repeated administration are not fully established, and research remains ongoing.

Common questions about Referen (FAQ)

Q: Are there any known common foods that may affect how Referen works?

Regulatory documents state that because Referen is administered directly into the bloodstream as an intravenous injection, official labeling indicates that its action is independent of food intake. This differs from oral iron supplements, which must be absorbed through the digestive system.

Q: Is Referen known to cause any reactions when combined with alcohol?

Official labeling does not list any specific or clinically relevant reactions when Referen is combined with alcohol. Due to the intravenous route, its action is described as independent of alcohol consumption.

Q: Does taking Referen with or without food change its described effects?

No. Because Referen is a solution for intravenous injection, it is administered directly into the vein. Its action is described as independent of food intake.

Q: Is Referen described for use in pediatric populations?

Official product information confirms that Referen is approved for use in pediatric patients with Chronic Kidney Disease (CKD) who are two years of age and older. Dosage for children is determined based on body weight.

Q: Have studies examined the use of Referen in elderly patient populations?

Clinical studies of Referen have included patients aged 65 years and older. Official safety information advises careful administration and monitoring; however, no notable differences in the safety profile were documented in these studies when compared to younger adults.

Q: Can Referen be used by women who are breastfeeding?

According to official information, adverse effects in breastfed infants are generally not expected based on current data. Studies have indicated that the concentration of iron in breastmilk is not increased after an intravenous infusion of iron sucrose.

Q: Are there any general warnings about using Referen before an upcoming surgery?

Official labeling does not list general restrictions regarding the timing of elective surgery. However, the most critical safety precaution is the risk of acute hypersensitivity reactions and hypotension, which is why patients are monitored during and for at least 30 minutes after the infusion.

Q: How long does Referen typically take to show its described effects?

Clinical trial data shows that objective changes in laboratory values (such as iron stores and Hemoglobin (Hb) levels) are generally seen within weeks of beginning the treatment course.

Q: Is Referen a treatment that is usually taken for a short period or long-term?

Referen is prescribed to correct an iron deficit, which involves an initial cumulative dose, often 1000 mg of elemental iron, given over a set period. Treatment may be repeated based on the patient's iron status and clinical assessment if the deficiency reoccurs.

Q: Can Referen cause temporary changes to vision or mental focus?

Common adverse reactions reported in official documents include Nervous System Disorders such as headache and dizziness. While these types of side effects can generally affect concentration, specific changes to vision are not explicitly listed among the most common adverse reactions.

Q: Is there any information about Referen's potential impact on fertility?

Non-clinical safety studies reviewed by regulatory agencies have not indicated a specific hazard to humans based on conventional studies of toxicity to reproduction and development.

Q: Have researchers looked at Referen's effectiveness in combination with other common therapies?

The only documented interaction involves oral iron preparations, which should not be administered at the same time as Referen. Official labeling states that no clinically relevant interactions with major non-iron drug categories are documented.

Q: What is the purpose of the initial testing that is sometimes done before starting Referen?

Initial and periodic testing of blood parameters, such as Hemoglobin (Hb), Serum Ferritin, and Transferrin Saturation (TSAT), is required for monitoring a patient's iron status. This monitoring is used to determine the necessity of the treatment and to identify the risk of iron overload.

Q: Are the described side effects of Referen the same for men and women?

The frequency and type of adverse reactions reported in official regulatory documents are generally presented for the overall study population. Official labeling does not specify distinct side effect profiles based on sex.

Q: What is the typical timeframe within which most side effects are reported to appear?

Official labeling emphasizes that the most serious reactions, such as anaphylactic-type events, usually occur within 30 minutes of the completion of the infusion. The timeframe for common, minor side effects is generally during or shortly after administration.

Q: Does body weight or BMI influence the general effects of Referen?

For pediatric patients (aged two years and older), the dosage is explicitly calculated based on body weight. For adult patients, standard dosing regimens are applied based on Chronic Kidney Disease status, independent of body weight.

Q: Are there different versions or strengths of Referen available?

Referen is supplied as a solution for injection with a single concentration of elemental iron (typically 20 mg/mL). While the final volume and amount administered may vary, the product is available in one concentration.

Q: Are serious skin reactions or allergies reported with Referen use?

Yes, official labeling includes the risk of serious hypersensitivity reactions (allergies). Additionally, common adverse reactions include generalized skin issues like pruritus (itching) and rash.

Q: Does Referen have known interactions with common herbal supplements?

Official regulatory information states that no clinically relevant interactions with herbal products are documented. This is due to the medication being administered directly into the bloodstream.

Q: Does the effect of Referen build up in the body over time?

The medication's mechanism is designed for the controlled release of iron. The treatment course is cumulative and is intended to replenish the total body iron stores over a period of administration.

Q: Is it possible to use Referen if a person has certain pre-existing heart conditions?

Official warnings address the risk of hypotension (low blood pressure) associated with intravenous administration. The risk of hypotension is generally mitigated by administering the medication at recommended infusion rates, as specified in regulatory documents. Specific eligibility is determined clinically.

Q: What are the signs that Referen is having its desired effect?

The desired effect is monitored objectively through blood tests that measure increases in Hemoglobin (Hb) and the replenishment of iron stores, specifically Serum Ferritin and Transferrin Saturation (TSAT) levels.

How to Store and Dispose of Referen

Referen (Iron Sucrose Injection) must be stored at controlled room temperature, specifically between 20°C to 25°C (68°F to 77°F). It is critical that the solution does not freeze.

---

Storage and Handling

Condition	Requirement (Official Labeling)
Temperature	Controlled room temperature; do not freeze
Protection	Store in the original carton to protect from light.
Child Safety	Keep out of the sight and reach of children.
Stability	Any unused portion in a single-use vial must be discarded. Diluted solution has a limited stability and should be used promptly.

---

Disposal

Unused or expired product must be disposed of in accordance with local pharmaceutical waste procedures or through an official drug take-back program. Used needles, syringes, and vials must be placed in a designated puncture-resistant sharps container immediately after use.